OneSource Specialty Pharma Limited (IN:ONESOURCE)
:ONESOURCE
Want to see IN:ONESOURCE full AI Analyst Report?
Top Page
OneSource Specialty Pharma Limited
(ONESOURCE)
Select Model
Select Model
Rating:54Neutral
Price Target:
₹1,857.00
▲(20.56% Upside)
Action:N/A
Date:05/15/26
The score is held back primarily by weak fundamentals—sharp profitability deterioration and significant negative operating/free cash flow—despite strong FY2026 revenue growth. Technicals are supportive with an established uptrend and positive momentum, but an extremely high P/E and lack of dividend yield reduce the valuation score and cap the overall rating.
Positive Factors
Revenue Growth
A ~77% revenue surge in FY2026 represents durable top-line expansion and stronger commercial traction. Sustained revenue growth provides a larger base for operating leverage, supports reinvestment in R&D and commercialization, and creates scope to improve margins over the next several quarters.
Negative Factors
Cash Generation Weakness
Persistent negative operating and free cash flow is a structural concern: the business is burning cash to operate and invest. Over the next 2-6 months this limits the company’s ability to self-fund growth, raises refinancing or dilution risk, and constrains discretionary spending like marketing or R&D.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
A ~77% revenue surge in FY2026 represents durable top-line expansion and stronger commercial traction. Sustained revenue growth provides a larger base for operating leverage, supports reinvestment in R&D and commercialization, and creates scope to improve margins over the next several quarters.
Read all positive factors
OneSource Specialty Pharma Limited (ONESOURCE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹214.11B
Dividend YieldN/A
Average Volume (3M)3.94K
Price to Earnings (P/E)920.2
Beta (1Y)0.50
Revenue Growth47.33%
EPS Growth57.44%
CountryIN
Employees1,412
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)9.53
Shares Outstanding114,642,654
10 Day Avg. Volume3,856
30 Day Avg. Volume3,937
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.89
Price to Sales (P/S)11.87
P/FCF Ratio-24.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)38.15
Revenue Forecast (FY)₹22.08B
OneSource Specialty Pharma Limited Business Overview & Revenue Model
Company Description
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internati...
OneSource Specialty Pharma Limited Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
68
Positive
Cash Flow
29
Negative
| Breakdown | TTM | Mar 2025 | Mar 2025 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 8.02B | 14.22B | 14.45B |
| Gross Profit | 4.58B | 4.56B | 10.10B |
| EBITDA | 2.92B | 3.04B | 3.61B |
| Net Income | 1.09B | -738.03M | -2.10M |
Balance Sheet | |||
| Total Assets | 80.13B | 82.10B | 75.50B |
| Cash, Cash Equivalents and Short-Term Investments | 1.80B | 1.03B | 36.21M |
| Total Debt | 12.95B | 15.04B | 9.42B |
| Total Liabilities | 21.09B | 23.79B | 209.75M |
| Stockholders Equity | 59.04B | 58.31B | 58.81B |
Cash Flow | |||
| Free Cash Flow | -3.69B | -6.80B | -1.96B |
| Operating Cash Flow | -399.21M | -1.11B | -24.69M |
| Investing Cash Flow | -2.51B | -4.95B | -25.05M |
| Financing Cash Flow | 2.31B | 4.79B | 66.47M |
OneSource Specialty Pharma Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ₹215.27B | 173.10 | ― | 0.35% | 34.49% | 107.17% | |
70 Outperform | ₹202.20B | 51.42 | ― | 0.47% | 12.37% | 30.97% | |
64 Neutral | ₹214.37B | 29.89 | ― | 0.69% | 10.45% | -5.88% | |
62 Neutral | ₹147.95B | 19.32 | ― | 1.28% | 10.08% | 15.65% | |
60 Neutral | ₹234.48B | -487.64 | ― | 0.08% | -3.08% | -458.85% | |
54 Neutral | ₹214.11B | 920.22 | ― | ― | 47.33% | 57.44% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:ONESOURCE
OneSource Specialty Pharma Limited
1,867.60
201.65
12.10%
IN:APLLTD
Alembic Pharmaceuticals Limited
752.70
-209.19
-21.75%
IN:ASTRAZEN
AstraZeneca Pharma India Limited
8,610.95
636.33
7.98%
IN:ERIS
Eris Lifesciences Ltd
1,459.50
-60.05
-3.95%
IN:PFIZER
PFIZER LIMITED
4,685.90
-301.53
-6.05%
IN:PPLPHARMA
Piramal Pharma Limited
176.40
-29.82
-14.46%
OneSource Specialty Pharma Limited Corporate Events
OneSource to Manufacture Dr. Reddy’s Generic Ozempic for Canada
Apr 29, 2026
OneSource Specialty Pharma Limited said partner Dr. Reddy’s Laboratories has received a Notice of Compliance from Health Canada for Semaglutide Injection, a generic version of diabetes and weight-loss drug Ozempic. OneSource serves as the CD...
OneSource Specialty Pharma Wins EU GMP Nod for Bangalore Sterile Facility
Apr 28, 2026
OneSource Specialty Pharma Limited’s Sterile Product Division facility in Bangalore has received an EU Good Manufacturing Practice (GMP) Certificate of Compliance for sterile products from the German state authority of Schleswig-Holstein, fo...
OneSource Specialty Pharma Withdraws CARE Ratings, Retains IND A- from India Ratings
Mar 5, 2026
OneSource Specialty Pharma Limited, a listed Indian pharmaceutical services company operating under the Onesource CDMO platform, maintains a credit rating of IND A- with a Positive outlook from India Ratings Research, reaffirmed in December 2025....
OneSource Specialty Pharma to Engage Investors at Investec Promoter & Founder Conference 2026
Mar 4, 2026
OneSource Specialty Pharma Limited has announced that its representatives will participate in the Investec India Promoter Founder Conference 2026 in Mumbai on March 9, 2026. During the event, the company plans to engage with investors by discussi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.